375 related articles for article (PubMed ID: 32776282)
1. Perspectives on the Clinical Development of NRF2-Targeting Drugs.
Lastra D; Fernández-Ginés R; Manda G; Cuadrado A
Handb Exp Pharmacol; 2021; 264():93-141. PubMed ID: 32776282
[TBL] [Abstract][Full Text] [Related]
2. Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development.
Robledinos-Antón N; Fernández-Ginés R; Manda G; Cuadrado A
Oxid Med Cell Longev; 2019; 2019():9372182. PubMed ID: 31396308
[TBL] [Abstract][Full Text] [Related]
3. The role of Nrf2 and PPARgamma in the improvement of oxidative stress in hypertension and cardiovascular diseases.
Dovinova I; Kvandová M; Balis P; Gresova L; Majzunova M; Horakova L; Chan JY; Barancik M
Physiol Res; 2020 Dec; 69(Suppl 4):S541-S553. PubMed ID: 33656904
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in the development of small molecule Nrf2 activators: a patent review (2017-present).
Zhou H; Wang Y; You Q; Jiang Z
Expert Opin Ther Pat; 2020 Mar; 30(3):209-225. PubMed ID: 31922884
[No Abstract] [Full Text] [Related]
5. Activation of KEAP1/NRF2 stress signaling involved in the molecular basis of hemin-induced cytotoxicity in human pro-erythroid K562 cells.
Georgiou-Siafis SK; Tsiftsoglou AS
Biochem Pharmacol; 2020 May; 175():113900. PubMed ID: 32156661
[TBL] [Abstract][Full Text] [Related]
6. KEAP1-NRF2 protein-protein interaction inhibitors: Design, pharmacological properties and therapeutic potential.
Crisman E; Duarte P; Dauden E; Cuadrado A; Rodríguez-Franco MI; López MG; León R
Med Res Rev; 2023 Jan; 43(1):237-287. PubMed ID: 36086898
[TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid receptor signaling represses the antioxidant response by inhibiting histone acetylation mediated by the transcriptional activator NRF2.
Alam MM; Okazaki K; Nguyen LTT; Ota N; Kitamura H; Murakami S; Shima H; Igarashi K; Sekine H; Motohashi H
J Biol Chem; 2017 May; 292(18):7519-7530. PubMed ID: 28314773
[TBL] [Abstract][Full Text] [Related]
8. Medicinal Chemistry Insights into the Development of Small-Molecule Kelch-Like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Protein-Protein Interaction Inhibitors.
Zhao Z; Dong R; You Q; Jiang Z
J Med Chem; 2023 Jul; 66(14):9325-9344. PubMed ID: 37441735
[TBL] [Abstract][Full Text] [Related]
9. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
11. Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases.
Pallesen JS; Tran KT; Bach A
J Med Chem; 2018 Sep; 61(18):8088-8103. PubMed ID: 29750408
[TBL] [Abstract][Full Text] [Related]
12. Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy.
Yoshizaki Y; Mori T; Ishigami-Yuasa M; Kikuchi E; Takahashi D; Zeniya M; Nomura N; Mori Y; Araki Y; Ando F; Mandai S; Kasagi Y; Arai Y; Sasaki E; Yoshida S; Kagechika H; Rai T; Uchida S; Sohara E
Sci Rep; 2017 Jun; 7(1):3945. PubMed ID: 28638054
[TBL] [Abstract][Full Text] [Related]
13. Nrf2-Keap1 antioxidant defense and cell survival signaling are upregulated by 17β-estradiol in homocysteine-treated dopaminergic SH-SY5Y cells.
Chen CS; Tseng YT; Hsu YY; Lo YC
Neuroendocrinology; 2013; 97(3):232-41. PubMed ID: 22948038
[TBL] [Abstract][Full Text] [Related]
14. Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress.
Suzuki T; Yamamoto M
J Biol Chem; 2017 Oct; 292(41):16817-16824. PubMed ID: 28842501
[TBL] [Abstract][Full Text] [Related]
15. CPUY192018, a potent inhibitor of the Keap1-Nrf2 protein-protein interaction, alleviates renal inflammation in mice by restricting oxidative stress and NF-κB activation.
Lu MC; Zhao J; Liu YT; Liu T; Tao MM; You QD; Jiang ZY
Redox Biol; 2019 Sep; 26():101266. PubMed ID: 31279986
[TBL] [Abstract][Full Text] [Related]
16. NF-κB and Keap1 Interaction Represses Nrf2-Mediated Antioxidant Response in Rabbit Hemorrhagic Disease Virus Infection.
Hu B; Wei H; Song Y; Chen M; Fan Z; Qiu R; Zhu W; Xu W; Wang F
J Virol; 2020 May; 94(10):. PubMed ID: 32161178
[TBL] [Abstract][Full Text] [Related]
17. S-1-propenylmercaptocysteine protects murine hepatocytes against oxidative stress via persulfidation of Keap1 and activation of Nrf2.
Tocmo R; Parkin K
Free Radic Biol Med; 2019 Nov; 143():164-175. PubMed ID: 31349040
[TBL] [Abstract][Full Text] [Related]
18. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Mechanisms Regulating the KEAP1-NRF2 Pathway.
Baird L; Yamamoto M
Mol Cell Biol; 2020 Jun; 40(13):. PubMed ID: 32284348
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of miR-200a protects cardiomyocytes against hypoxia-induced apoptosis by modulating the kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 signaling axis.
Sun X; Zuo H; Liu C; Yang Y
Int J Mol Med; 2016 Oct; 38(4):1303-11. PubMed ID: 27573160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]